Cystic Fibrosis Patient Testimony on Orkambi
Orkambi is a combination therapy for treatment of cystic fibrosis. The FDA approval for the therapy was announced on July 2nd, 2015.
This is Kate Marshall’s Orkambi testimony before the Open Public Hearing OPH portion of the May 12, 2015 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting in Washington, DC.
Kate is 15 years old and has two copies of the D508 gene, which Orkambi, (the combination of Ivacaftor and Lumacaftor) treats.
Learn more about Orkambi here: http://bit.ly/1jCoQUT
Read all the latest news about Orkambi here: http://bit.ly/1RlPwnh